Peter Fellner nominated to be elected to Biotie's Board of Directors
(Thomson Reuters ONE) - BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE September 28, 2009at 9.00 a.m.Peter Fellner nominated to be elected to Biotie's Board of DirectorsThe Board of Directors proposes for the Extraordinary General Meetingon October 29, 2009 on the basis of the recommendation of the Board'sNomination and Remuneration Committee that the number of members ofthe Board of Directors would be eight (8) and that Dr. Peter Fellnerwould be elected as a new member of the Board of Directors for theterm expiring at the end of the following Annual General Meeting.Dr. Fellner, 65, currently serves as Chairman of Consort Medical Plc,Chairman of Vernalis Plc and Chairman of Astex Therapeutics Ltd.Previously he served as CEO of Celltech Group plc from 1990 to 2003,and then as its Chairman until 2004. Prior to this he was CEO ofRoche UK from 1986 to 1990. He has also served as a director ofseveral other public companies.Dr. Fellner has given his consent to Board service. He is independentof the company and independent of significant shareholders of thecompany.This proposal is included in the invitation to the ExtraordinaryGeneral Meeting, dated 28 September, 2009.Turku, September 28, 2009Biotie Therapies Corp.Timo VeromaaPresident and CEOFor further information, please contact:Timo Veromaa, President and CEO, Biotie Therapies Corp.tel. +358 2 274 8901, e-mail: timo.veromaa(at)biotie.comwww.biotie.comwww.biotie.comDistribution:NASDAQ OMX Helsinki LtdMain Mediawww.biotie.comBiotie Therapies Corp.Biotie is a drug discovery and development company focused on centralnervous system and inflammatory diseases. It has a broad range ofinnovative small molecule and biological drug candidates at differentstages of clinical and pre-clinical development. Biotie's productsaddress diseases with high unmet medical need and significant marketpotential, including addiction and psychotic disorders, rheumatoidarthritis, psoriasis and chronic obstructive pulmonary disease(COPD). The most advanced product, nalmefene for alcohol dependence,is currently in phase III clinical development by licensing partnerH. Lundbeck A/S.The commercial value of the pipeline has been demonstrated throughexisting alliances with top-tier global pharmaceutical companies suchas Lundbeck, Roche and Wyeth. Biotie has operations in Turku, Finlandand Radebeul, Germany.Biotie shares are listed on NASDAQ OMX Helsinki Ltd.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 28.09.2009 - 08:02 Uhr
Sprache: Deutsch
News-ID 6275
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 609 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Peter Fellner nominated to be elected to Biotie's Board of Directors"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotie Therapies Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
